Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-10-26 AGM Information
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
关于召开2022 年第一次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting of shareholders for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval, legal compliance, and procedural details. The content focuses on the announcement and organization of a shareholders' meeting rather than the meeting materials or results. There is no financial data, audit information, or transcript of discussions. The document is not a report but a formal meeting notice and invitation to shareholders to participate and vote. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including notices and meeting announcements.
2022-10-26 Chinese
第三届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the third Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related disclosures on the Beijing Stock Exchange website. The content focuses on governance matters such as amendments to the Supervisory Board system, equity incentive plans, and core employee recognition. It is not a full report like an annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement of board/management decisions and governance-related resolutions. Therefore, the document fits best under Board/Management Information (MANG). The document length is 2569 characters, which is consistent with a meeting resolution announcement rather than a full report.
2022-10-26 Chinese
承诺管理制度
Governance Information Classification · 95% confidence The document is titled '承诺管理制度' (Commitment Management System) and details the company's internal policy regarding commitments made by the company, its controlling shareholders, related parties, directors, supervisors, senior management, and others. It includes sections on the scope, content, disclosure, fulfillment, and modification of commitments. The document references relevant laws and regulations and was approved by the company's board of directors. There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. The document is a governance-related policy document outlining internal rules and procedures. Therefore, it fits best under Governance Information (CGR). The document length is 2399 characters, which is relatively short but contains substantive governance content rather than being a mere announcement or certification. Hence, the classification is CGR with high confidence.
2022-10-26 Chinese
重大资金往来管理制度
Governance Information Classification · 95% confidence The document is titled '重大资金往来管理制度' which translates to 'Major Funds Transaction Management System' and details internal policies and procedures related to the management and prevention of funds misuse between the company and its controlling shareholders or related parties. It includes sections on principles, responsibilities, and penalties related to fund management. The document references a board meeting date (October 26, 2022) where the policy was approved, and it is a formal internal governance document. There are no financial statements, earnings data, or audit results presented. It is not an announcement of a report but a detailed governance policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-10-26 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is a detailed disclosure management system of Beijing Sanyuan Gene Pharmaceutical Co., Ltd., outlining the company's information disclosure policies, procedures, responsibilities, and regulatory compliance requirements. It extensively references regulatory frameworks such as the Securities Law of the People's Republic of China, Beijing Stock Exchange listing rules, and audit requirements. The content focuses on the governance and procedural aspects of information disclosure, including board and management responsibilities, reporting timelines, and handling of material events. It does not contain actual financial statements, earnings data, or audit results but rather the internal rules and governance practices related to disclosure. Therefore, this document fits the category of Governance Information (CGR).
2022-10-26 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It is a detailed internal policy document outlining the principles, definitions, procedures, and disclosure requirements for related party transactions within the company. It includes sections on the scope, definitions of related parties, pricing principles, approval procedures, voting and recusal rules, disclosure obligations, and other governance aspects related to related party transactions. The document is issued by the company's board and includes references to regulatory rules and company bylaws. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing related party transactions, which falls under governance information rather than regulatory filings or other categories. The document length (8619 characters) and content confirm it is a substantive policy document, not a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2022-10-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.